Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

Abstract

IntroductionMutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20–25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear.MethodsWe undertook a single-institution retrospective analysis of 93 consecutive patients with stage IV NSCLC adenocarcinoma with known KRAS and EGFR MT status to determine the association of KRAS MT with survival. All patients were treated between January 1, 2008 and December 31, 2011 with standard platinum based chemotherapy at the University of Pennsylvania. Overall and progression free survival were analyzed using Kaplan-Meier and Cox proportional hazard methods.ResultsAll patients in this series received platinum doublet chemotherapy, and 42 (45%) received bevacizumab. Overall survival and progression free survival for patients with KRAS MT was no worse than for patients with wild type KRAS. Median overall survival for patients with KRAS MT was 19 months (mo) vs. 15.6 mo for KRAS WT, p = 0.34, and progression-free survival was 6.2 mo in patients with KRAS MT vs. 7mo in patients with KRAS WT, p = 0.51. In multivariable analysis including age, race, gender, and ECOG PS, KRAS MT was not associated with overall survival (HR 1.12, 95% CI 0.58–2.16, p = 0.74) or progression free survival (HR 0.80, 95% CI 0.48–1.34, p = 41). Of note, receipt of bevacizumab was associated with improved overall survival only in KRAS WT patients (HR 0.34, p = 0.01).ConclusionsKRAS MT are not associated with inferior progression-free and overall survival in advanced NSCLC patients treated with standard first-line platinum-based chemotherapy.

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences

“… 12 These different downstream effects may result in different prognostic significance and response to therapy among KRAS mutations. 13 …”

A systematic review of targeted agents for non-small cell lung cancer

“…KRAS acts downstream of the EGFR and is mutated in 20-25% of all NSCLC patients [64,65]. Thus, it plays a pivotal role in the development of cancer in a great subgroup of NSCLC cancer cases [66]. In a randomized, open-label, multicenter, twoarmed phase II study, conducted by Blumenschein et al [65], treatment with the MEK1/MEK2 inhibitor, Trametinib, was used to treat KRAS-mutated patients (Supplementary Table 1).…”

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

“…There is no current consensus regarding the optimal treatment strategy for NSCLC [12, 13, 14]. Current therapeutic options in NSCLC, reviewed briefly below, are plagued by the emergence of resistance and cross-resistance[15, 16], practically a fait accompli and an inevitable consequence of exposure to treatment, highlighting the urgent need for strategies that are able to circumvent and overcome it [17, 18, 19, 20]. …”